[[19], [20], [21],25] Including 48 patients with 97 bone and lymph node lesions our cohort belongs to one of the largest relatively homogenous cohorts of metastatic prostate cancer patients who were (a) treated with ablative radiation doses to PSMA-PET/CT-detected oligometastases and (b) had a functional response assessment with multiple PSMA-PET/CT-scans. Here, FOLH1 is linked to metastatic prostate carcinoma.